Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis.

Garvey EP, Sharp AD, Warn PA, Yates CM, Schotzinger RJ.

J Antimicrob Chemother. 2018 Oct 1;73(10):2815-2822. doi: 10.1093/jac/dky242.

PMID:
29947783
2.

MRSA decolonization of cotton rat nares by a combination treatment comprising lysostaphin and the antimicrobial peptide ranalexin.

Desbois AP, Sattar A, Graham S, Warn PA, Coote PJ.

J Antimicrob Chemother. 2013 Nov;68(11):2569-75. doi: 10.1093/jac/dkt243. Epub 2013 Jun 25.

PMID:
23800902
3.

Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.

Sudan A, Livermore J, Howard SJ, Al-Nakeeb Z, Sharp A, Goodwin J, Gregson L, Warn PA, Felton TW, Perfect JR, Harrison TS, Hope WW.

Antimicrob Agents Chemother. 2013 Jun;57(6):2793-800. doi: 10.1128/AAC.00216-13. Epub 2013 Apr 9.

4.

Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.

Livermore JL, Felton TW, Abbott J, Sharp A, Goodwin J, Gregson L, Warn PA, Howard SJ, Hope WW.

Antimicrob Agents Chemother. 2013 Jan;57(1):281-8. doi: 10.1128/AAC.01387-12. Epub 2012 Oct 31.

5.

The Aspergillus fumigatus dihydroxyacid dehydratase Ilv3A/IlvC is required for full virulence.

Oliver JD, Kaye SJ, Tuckwell D, Johns AE, Macdonald DA, Livermore J, Warn PA, Birch M, Bromley MJ.

PLoS One. 2012;7(9):e43559. doi: 10.1371/journal.pone.0043559. Epub 2012 Sep 18.

6.

Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.

Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Warn PA, Hope WW.

Antimicrob Agents Chemother. 2012 Oct;56(10):5180-5. doi: 10.1128/AAC.01111-12. Epub 2012 Jul 23.

7.

Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.

Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Majithiya JB, Lass-Flörl C, Cuenca-Estrella M, Arendrup MC, Warn PA, Hope WW.

J Infect Dis. 2012 Aug 1;206(3):442-52. doi: 10.1093/infdis/jis372. Epub 2012 May 25.

PMID:
22634880
8.

Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration.

Al-Nakeeb Z, Sudan A, Jeans AR, Gregson L, Goodwin J, Warn PA, Felton TW, Howard SJ, Hope WW.

Antimicrob Agents Chemother. 2012 Aug;56(8):4146-53. doi: 10.1128/AAC.00141-12. Epub 2012 May 21.

9.

Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.

Warn PA, Livermore J, Howard S, Felton TW, Sharp A, Gregson L, Goodwin J, Petraitiene R, Petraitis V, Cohen-Wolkowiez M, Walsh TJ, Benjamin DK Jr, Hope WW.

Antimicrob Agents Chemother. 2012 Feb;56(2):708-14. doi: 10.1128/AAC.05826-11. Epub 2011 Nov 28.

10.

Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter.

Albarrag AM, Anderson MJ, Howard SJ, Robson GD, Warn PA, Sanglard D, Denning DW.

Antimicrob Agents Chemother. 2011 Nov;55(11):5113-21. doi: 10.1128/AAC.00517-11. Epub 2011 Aug 29.

11.

Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.

Howard SJ, Livermore J, Sharp A, Goodwin J, Gregson L, Alastruey-Izquierdo A, Perlin DS, Warn PA, Hope WW.

Antimicrob Agents Chemother. 2011 Oct;55(10):4880-7. doi: 10.1128/AAC.00621-11. Epub 2011 Aug 1.

12.

Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin.

Slater JL, Howard SJ, Sharp A, Goodwin J, Gregson LM, Alastruey-Izquierdo A, Arendrup MC, Warn PA, Perlin DS, Hope WW.

Antimicrob Agents Chemother. 2011 Jul;55(7):3075-83. doi: 10.1128/AAC.01686-10. Epub 2011 Apr 18.

13.

Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.

Howard SJ, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J, Majithiya JB, Warn PA, Hope WW.

J Infect Dis. 2011 May 1;203(9):1324-32. doi: 10.1093/infdis/jir023. Epub 2011 Feb 28.

14.

Pathogenicity of Aspergillus fumigatus mutants assessed in Galleria mellonella matches that in mice.

Slater JL, Gregson L, Denning DW, Warn PA.

Med Mycol. 2011 Apr;49 Suppl 1:S107-13. doi: 10.3109/13693786.2010.523852. Epub 2010 Oct 18.

PMID:
20950221
15.
16.

Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.

Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW.

Antimicrob Agents Chemother. 2009 Aug;53(8):3453-61. doi: 10.1128/AAC.01601-08. Epub 2009 May 18.

17.

Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.

Majithiya J, Sharp A, Parmar A, Denning DW, Warn PA.

J Antimicrob Chemother. 2009 Jan;63(1):161-6. doi: 10.1093/jac/dkn431. Epub 2008 Nov 13.

18.

Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.

Hope WW, Warn PA, Sharp A, Reed P, Keevil B, Louie A, Walsh TJ, Denning DW, Drusano GL.

Antimicrob Agents Chemother. 2007 Oct;51(10):3760-2. Epub 2007 Aug 6.

19.

Aspergillus flavus: human pathogen, allergen and mycotoxin producer.

Hedayati MT, Pasqualotto AC, Warn PA, Bowyer P, Denning DW.

Microbiology. 2007 Jun;153(Pt 6):1677-92. Review.

PMID:
17526826
20.

Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.

Hope WW, Drusano GL, Moore CB, Sharp A, Louie A, Walsh TJ, Denning DW, Warn PA.

Antimicrob Agents Chemother. 2007 Jan;51(1):285-95. Epub 2006 Nov 6.

21.

Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.

Warn PA, Sharp A, Mosquera J, Spickermann J, Schmitt-Hoffmann A, Heep M, Denning DW.

J Antimicrob Chemother. 2006 Dec;58(6):1198-207. Epub 2006 Oct 27.

PMID:
17071636
22.

Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect.

Hope WW, Warn PA, Sharp A, Howard S, Kasai M, Louie A, Walsh TJ, Drusano GL, Denning DW.

Antimicrob Agents Chemother. 2006 Nov;50(11):3680-8. Epub 2006 Sep 5.

23.

In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.

Warn PA, Sharp A, Denning DW.

J Antimicrob Chemother. 2006 Jan;57(1):135-8. Epub 2005 Nov 10.

PMID:
16284102
24.
25.

Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis.

Hope WW, Warn PA, Sharp A, Reed P, Keevil B, Louie A, Denning DW, Drusano GL.

J Infect Dis. 2005 Aug 15;192(4):673-80. Epub 2005 Jul 7.

PMID:
16028137
26.

Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida.

Warn PA, Sharp A, Guinea J, Denning DW.

J Antimicrob Chemother. 2004 May;53(5):743-9. Epub 2004 Mar 24.

PMID:
15044422
27.

Infrared body temperature measurement of mice as an early predictor of death in experimental fungal infections.

Warn PA, Brampton MW, Sharp A, Morrissey G, Steel N, Denning DW, Priest T.

Lab Anim. 2003 Apr;37(2):126-31.

PMID:
12689423
28.
29.

In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis.

Warn PA, Sharp A, Morrissey G, Denning DW.

J Antimicrob Chemother. 2002 Dec;50(6):1071-4.

PMID:
12461036
30.

In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp.

Mosquera J, Sharp A, Moore CB, Warn PA, Denning DW.

J Antimicrob Chemother. 2002 Aug;50(2):189-94.

PMID:
12161398
31.

Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole.

Mosquera J, Warn PA, Rodriguez-Tudela JL, Denning DW.

J Antimicrob Chemother. 2001 Oct;48(4):583-6.

PMID:
11581243
32.

Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo.

Mosquera J, Warn PA, Morrissey J, Moore CB, Gil-Lamaignere C, Denning DW.

Antimicrob Agents Chemother. 2001 May;45(5):1456-62.

33.
34.

The epidemiology of hookworm infection and its contribution to anaemia among pre-school children on the Kenyan coast.

Brooker S, Peshu N, Warn PA, Mosobo M, Guyatt HL, Marsh K, Snow RW.

Trans R Soc Trop Med Hyg. 1999 May-Jun;93(3):240-6.

PMID:
10492749
35.

Severe anaemia in children living in a malaria endemic area of Kenya.

Newton CR, Warn PA, Winstanley PA, Peshu N, Snow RW, Pasvol G, Marsh K.

Trop Med Int Health. 1997 Feb;2(2):165-78.

36.
37.

Periodicity and space-time clustering of severe childhood malaria on the coast of Kenya.

Snow RW, Schellenberg JR, Peshu N, Forster D, Newton CR, Winstanley PA, Mwangi I, Waruiru C, Warn PA, Newbold C, et al.

Trans R Soc Trop Med Hyg. 1993 Jul-Aug;87(4):386-90.

PMID:
8249058
38.

A single dose of intramuscular sulfadoxine-pyrimethamine as an adjunct to quinine in the treatment of severe malaria: pharmacokinetics and efficacy.

Newton CR, Winstanley PA, Watkins WM, Mwangi IN, Waruiru CM, Mberu EK, Warn PA, Nevill CG, Marsh K.

Trans R Soc Trop Med Hyg. 1993 Mar-Apr;87(2):207-10.

PMID:
8337731
39.

The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria.

Winstanley PA, Watkins WM, Newton CR, Nevill C, Mberu E, Warn PA, Waruiru CM, Mwangi IN, Warrell DA, Marsh K.

Br J Clin Pharmacol. 1992 Feb;33(2):143-8.

Supplemental Content

Support Center